CONSTITUENT REPORT
Cuminaldehyde
Cuminaldehyde is the defining spicy aldehyde of cumin-type oils and one of the better-studied AromaForge constituents in this batch. Public sources strongly support its registry identity and dominant occurrence in cumin seed oil, while preclinical literature adds antibacterial, anti-inflammatory, antinociceptive, and enzyme-modulation signals. Safety evidence is meaningful but still fragrance-oriented rather than therapeutic: IFRA restricts its use, and RIFM-linked materials characterize it as a weak sensitizer with human and animal data in the background. AromaForge should therefore frame cuminaldehyde as a cumin-signature aromatic aldehyde with moderate preclinical evidence and explicit non-medical caution.
Chemical identity and composition
PubChem and NIST identify cuminaldehyde as C10H12O with CAS 122-03-2 and the para-isopropyl benzaldehyde naming family. In the archive it is the lead aldehyde of cumin seed oil, where reviewed GC-MS data place it near half of the oil in one Indian seed-oil profile.
Aroma and practical use
- Use the recorded spicy, cumin-like, herbal, warm, green, herbaceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2019 antibacterial study identified cuminaldehyde as the most active TLC-bioautography component from Thai Cuminum cyminum oil against Bacillus cereus, Staphylococcus aureus, Escherichia coli, and Salmonella Typhi.
The underlying oil contained 27.10% cuminaldehyde, and the abstract explicitly singled it out as the major bioactive antibacterial component.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023 open-access rat osteoarthritis study found cuminaldehyde as effective as indomethacin across the reported pain tests and also reported cytokine modulation, radiographic improvement, and histopathological improvement.
The same paper also reported preferential COX-2 inhibition in vitro and favorable in silico affinity with opioid receptors and COX-2.
This experimental finding does not establish benefit, dose or safety in people using this blend.
RIFM-linked fragrance-safety material summarized cuminaldehyde as a weak skin sensitizer with a weight-of-evidence NESIL of 1100 microg/cm2, LLNA non-sensitizing up to 10%, and no reactions in the cited confirmatory HRIPT at 1181 microg/cm2.
This information appears in a 4-ethylbenzaldehyde assessment that uses cuminaldehyde as the explicit read-across material for skin sensitization.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedIFRA lists cuminaldehyde as a restricted fragrance ingredient rather than an unrestricted one.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
RIFM-linked public material characterizes cuminaldehyde as a weak sensitizer by read-across framework and cites both animal and human test data behind the NESIL.
The source assessment applies to its specified exposure and preparation; this entry is not an unrestricted-use clearance.
No direct public citation is attached to this entry.
Most efficacy-style evidence for cuminaldehyde remains in vitro or animal-based, so archive language should stay non-medical and avoid treatment claims.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
citralAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read citral report →gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read gamma-Terpinene report →NeralAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Neral report →geranialAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read geranial report →p-CymeneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · effect
No source citation attached.
Read p-Cymene report →How the effects were investigated
preferential COX-2 inhibition with broader anti-inflammatory pathway modulation
An open-access osteoarthritis paper reported preferential COX-2 inhibition in vitro and discussed cytokine modulation in vivo.
This experimental finding does not establish benefit, dose or safety in people using this blend.
opioid-receptor and L-arginine/NO/cGMP pathway involvement in antinociceptive models
This mechanism is supported by the cited rat antinociceptive literature summarized in the open osteoarthritis paper and PubMed abstract record, but remains preclinical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
direct or indirect bacterial growth suppression in food-borne pathogens
A cumin-oil antibacterial paper identified cuminaldehyde as the most active TLC-bioautography component against the tested pathogens.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No constituent-specific human clinical trial evidence was verified for isolated cuminaldehyde in this pass.
- Much of the mechanistic literature remains preclinical, and some target claims are supported by mixed in vitro, animal, or in silico layers rather than direct human validation.
- The public safety picture is useful but partly mediated through IFRA and RIFM fragrance frameworks rather than open standalone toxicology monographs devoted only to cuminaldehyde.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.